Vanda Pharmaceuticals (VNDA) 10-K2016 FY Annual report

Filed: 17 Feb 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abuse, appellate, arise, avoid, Berlin, bipolar, broadly, calendar, cancer, cariprazine, ceiling, Children, Circuit, clarification, clarify, CMP, CMS, Coast, concealing, content, Corrupt, counter, currency, curtailment, dealing, declaratory, defraud, DOJ, dollar, drawn, dual, embezzling, enjoining, explain, explanation, factor, falsifying, FCP, FCPA, feedback, field, flow, formulary, found, FSS, FTC, fundamental, German, group, Guard, harbor, hematologic, HIPAA, HRSA, Hunton, illegal, implicate, imprisonment, incorrect, instance, intentionally, inter, IPR, Justice, kind, knowledge, London, mandatory, mid, middle, Mississauga, narrowly, negotiate, network, noncancellable, noninfringement, obstructing, offense, official, onForm, Ontario, opted, outpatient, overcharge, overcharging, pattern, payor, penny, Petition, pharmacoeconomic, Portability, poverty, presidential, pretax, properly, proportion, proven, PTAB, qui, recordkeeping, referral, Rehearing, remuneration, rest, restructuring, resubmit, reward, rural, scheme, se, Southern, statistically, stealing, stipulation, storage, Sunshine, tam, teaching, toForm, translated, translation, treble, Tricare, unapproved, unclear, unfold, uninsured, USA, variety, Vraylar, wider, willfully, XR

Removed: ACA, added, afford, alleging, amortizing, antitrust, applicability, arrange, asserting, brand, capacity, claimed, comprise, comprised, creation, demonstrated, disadvantage, doughnut, encouraged, establishment, heavy, hole, Improvement, inhibit, instituted, landscape, limiting, lost, mentioned, noncompliance, partnering, persuade, put, rebated, recommend, reflecting, reformed, seizure, separately, strive, sweeping, tenant, therapy, Topic

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VNDA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567, No. 333-171962, No. 333-179265, No. 333-186509, No. 333-193614, No. 333-201754, No. 333-209144 and No. 333-212255) and on Form S-3 (No. 333-205513) of Vanda Pharmaceuticals Inc. of our report dated February 17, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Baltimore, Maryland

February 17, 2017